Scale -

  • Revenue is 6813 Rs Cr; Annual Growth is 23 %; Continuous Growth over 3 years; in Top Quartile
  • Ebitda is 1826 Rs Cr; Annual Growth is 64 %; Continuous Growth over 3 years; in Top Quartile
  • PBT is 481 Rs Cr; Annual Growth is 144 %; Continuous Growth over 3 years; in Top Quartile
  • PAT is 890 Rs Cr; Annual Growth is 151 %; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Revenue is 2026 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile

Profitability -

  • PBDIT Margin is 26.8 %; Annual Growth is 34 %; Continuous Growth over 3 years
  • PAT Margin is 13.06 %; Annual Growth is 105 %; Continuous Growth over 3 years
  • Quarterly Ebitda Margin is 31 %; Continuous Growth over 3 Quarters; in Top Quartile
  • Quarterly Profit margin is 18 %; Continuous Growth over 3 Quarters; in Top Quartile

Return -

  • ROCE is 19.57 %; Annual Growth is 66 %; Continuous Growth over 3 years; in Top Quartile
  • ROA is 8.45 %; Annual Growth is 121 %; Continuous Growth over 3 years
  • ROE is 16.76 %; Annual Growth is 109 %; Continuous Growth over 3 years; in Top Quartile

Efficiency -

  • Operating cash flow is 1624 Rs Cr; Annual Growth is 170 %; in Top Quartile
  • Inventory Turnover Ratio is 3.18; Continuous Growth over 3 years; 5 Year CAGR is 23 %
  • Quick Ratio is 0.68; in Bottom Quartile

Solvancy -

  • Debt/Equity is 0.45; Continuous Decline over 3 years; in Top Quartile
  • Long term Debt is 611 Rs Cr; Continuous Decline over 3 years; in Top Quartile
  • Contingent Liabilities is 863 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Total Debt is 2397 Rs Cr; in Top Quartile

Quality -

  • Operating cashflow/ebitda is 89 %; Annual Growth is 65 %; in Top Quartile
  • Current Tax/PAT is 33 %; Annual Decline is -24 %; Continuous Decline over 3 years
  • Change in Inventories/Total Expenses is -5 %; Annual Decline is -338 %; in Bottom Quartile
  • Operating cashflow/PAT is 182 %; in Top Quartile
  • Other Expenses/Total Expenses is 25 %; Continuous Growth over 3 years
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Laurus Labs Q2 Profit Jumps 126% to ?441 Crore; EBITDA Rises 78%
Read More
  • Past/current
Laurus Labs Q2 profit surges 126% to Rs 441 crore; revenue jumps 33% to Rs 2,206 crore
Read More
  • Past/current
Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell
Read More
  • Past/current
Laurus Labs share price at record high after Q2 results 20?26, dividend announcement
Read More
  • Past/current
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Read More
  • Past/current
Laurus Labs Shares Rise 5% After Q2 FY27 Net Profit Jumps 126%
Read More
  • Past/current
Laurus rallies 19% in 4 days; zooms 111% YTD; what's driving CDMO stock?
Read More
  • Past/current
Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
Read More
  • Past/current
Stock Picks Today: Asian Paints, Trent, TCS, Suzlon Energy, And More On Brokerages' Radar
Read More
  • Past/current
Earnings call transcript: Laurus Labs posts record Q2 FY27 revenue, shares rise By Investing.com
Read More
  • Past/current
Laurus Labs among dividend names in focus during the results season
Read More
  • Past/current
Laurus Labs appoints Kundan Kumar Jha as Joint Company Secretary
Read More
  • Past/current
Laurus Labs declares ?1 interim dividend; Q2FY27 net profit rises 125%
Read More
  • Past/current
Laurus Labs Declares Interim Dividend Of Rs 1 Per Share; Check Record Date
Read More
  • Past/current
Laurus Labs Ltd (BOM:540222) (Q2 2027) Earnings Call Highlights: Record Revenue and PAT as CDMO ...
Read More
  • Past/current
Laurus Labs Ltd approves interim dividend of Rs. 1
Read More
  • Past/current
Laurus Labs Q2 FY27 Profit Jumps 126% to ?441 Crore as CDMO Revenue Surges 75%; Picks Up 60% Stake in Canada's Galenvs
Read More
  • Past/current
Laurus Labs Q2 FY27 Results and Interim Dividend Declared
Read More
  • Past/current
Laurus Labs Q2 FY27 slides: record revenue, 34.5% EBITDA margin By Investing.com
Read More
  • Past/current
Laurus Labs Q2 net profit surges 126% backed by growth in CDMO, affordable medicines businesses
Read More
  • Past/current
Laurus Labs Q2 net profit surges on 33% rise in revenue
Read More
  • Past/current
Laurus Labs Q2 Profit Doubles, Acquires Galenvs, SI&C Resins
Read More
  • Past/current
Laurus Labs Q2 results: Net profit jumps 126% on CDMO surge; buys Canadian firm to deepen oligonucleotide...
Read More
  • Past/current
Laurus Labs Q2 Results: Net Profit Jumps Multifold, Margin Expands To 34%
Read More
  • Past/current
Laurus Labs Q2 Results: Profit more than doubles, margin beats estimates; dividend declared
Read More
  • Past/current
Laurus Labs Reports 33.5% Q2 Revenue Growth; Consolidated PAT Rises 125.4% Year on Year
Read More
  • Past/current
Laurus Labs shares close higher as Q2 net profit jumps 126%
Read More
  • Past/current
Laurus Labs to acquire 52% stake in Hyderabad-based SI&C Resins for ?32.5 crore
Read More
  • Past/current
Laurus Labs to acquire 60% stake in Canadian biotech company Galenvs Sciences
Read More
  • Past/current
Laurus Labs’ Q2 net more than doubles at ?441 cr
Read More
  • Past/current
LAURUSLABS: Q2 revenue and profit rose sharply; interim dividend approved at ?1 per share
Read More
  • Past/current
LAURUSLABS: Record Q2 results as CDMO growth and complex-modality capacity build-out accelerate
Read More
  • Past/current
News by CNBC TV18 on TradingView, 2026-10-29 — cnbctv:8a211f18f094b:0
Read More
  • Past/current
Bharti Airtel, MCX, Laurus Labs look bullish on charts: Chandan Taparia
Read More
  • Past/current
Laurus Labs Ltd Sees Sharp Open Interest Surge Signalling Strong Market Positioning
Read More
  • Past/current
Soumya Chava on Laurus Labs’ push into finished-dose drugs
Read More
  • Past/current
Laurus Labs rallies 4% for 2nd straight day; stock hits new high
Read More
  • Past/current
Top 3 stocks to buy tomorrow: Laurus Labs, MCX, Coforge by market expert; check stop-loss, target price for Tue, 27 Oct
Read More
  • Past/current
Laurus Labs Limited (LAURUSLABS.BO) Stock Price, News, Quote & History
Read More
  • Past/current
LAURUSLABS Outlook for the Week
Read More
  • Past/current
Laurus Labs invests INR 1.08 billion: Nuvama targets Laurus Labs stock at INR 2,520
Read More
  • Past/current
Buy, Sell Or Hold: HDFC Bank, Laurus Labs, BEL, Havells India, Cummins India And Hindustan Copper — Ask Profit
Read More
  • Past/current
Laurus Labs zooms 128% from March low; hits new high in weak market
Read More
  • Past/current
Laurus Labs Invests Rs 107.8 Crore in KRKA Pharma Through Rights Issue
Read More
  • Past/current
Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside
Read More
  • Past/current
Laurus Labs invests $11.3 million in KRKA Pharma JV
Read More
  • Past/current
Laurus Labs invests ?1,078 crore in Krka Pharma, retains 49% stake
Read More
  • Past/current
Laurus Labs schedules Q2 FY27 earnings call for October 29
Read More
  • Past/current
Trade Spotlight: How should you trade Laurus Labs, BHEL, ACME Solar Holdings, Indian Hotels, Britannia,...
Read More
  • Past/current
Laurus Labs invests ?12.09 crore in Kurnool Renewables via rights issue
Read More
  • Past/current